63 results
8-K
EX-99.1
PRTK
Paratek Pharmaceuticals, Inc.
24 Feb 21
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
5:29pm
.”
Key 2021 Priorities
Expansion of NUZYRA into Primary Care Setting: Paratek completed the hiring of approximately 40 U.S. sales representatives
8-K
PRTK
Paratek Pharmaceuticals, Inc.
5 Feb 09
Entry into a Material Definitive Agreement
12:00am
of such acquisition, all unvested shares subject to stock options awarded in connection with the hiring of such individual shall immediately become fully
424B5
PRTK
Paratek Pharmaceuticals, Inc.
17 May 21
Prospectus supplement for primary offering
8:02am
payables, making potential regulatory submissions, hiring additional personnel, funding other product development and capital expenditures. We may also … , funding research and development, funding clinical trials, covering vendor payables, making potential regulatory submissions, hiring additional
424B5
wpb82e1a i8fswkej
3 Jul 19
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
273r05fsx0bvb l09
1 Jun 07
Entry into a Material Definitive Agreement
12:00am
8-K/A
EX-99.2
6bh3hx zs47ayz
31 Mar 09
Financial Statements and Exhibits
12:00am